#1 Clinical Trials Search in Europe

Study on Senicapoc for Patients with Progressive Fibrotic Interstitial Lung Disease to Prevent Disease Progression

2 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called Senicapoc in patients with a condition known as Progressive Fibrotic Interstitial Lung Disease (PF-ILD) or Idiopathic Pulmonary Fibrosis (IPF). These are lung diseases where the tissue in the lungs becomes scarred and stiff over time, making it difficult to breathe. The trial will compare the effects of Senicapoc to a placebo, which is a tablet that looks like the medication but does not contain any active ingredients.

The purpose of the study is to evaluate the safety and effectiveness of Senicapoc in addition to the usual care patients receive. Participants will take the medication or placebo orally in tablet form for a period of 26 weeks. During this time, researchers will monitor the rate at which the patients’ lung function declines, specifically looking at a measure called forced vital capacity (FVC), which is the amount of air a person can forcibly exhale from their lungs after taking the deepest breath possible.

Throughout the study, other aspects of the patients’ health will also be observed, such as changes in their quality of life, any hospitalizations, and any side effects they might experience. The study aims to provide valuable information on whether Senicapoc can help slow down the progression of these lung diseases and improve the overall well-being of the patients involved.

1 joining the study

Upon joining the study, the patient will have already been diagnosed with Progressive Fibrotic Interstitial Lung Disease within the last five years.

The patient must have a history of a chest HRCT scan performed within 24 months prior to inclusion and meet specific lung function criteria.

2 initial assessment

The patient will undergo an initial assessment to confirm eligibility, which includes reviewing medical history and lung function tests.

The patient must have an annual decline in lung function of at least 5% based on previous measurements.

3 treatment phase

The patient will receive either Senicapoc or a placebo in the form of a tablet for oral use.

The treatment will be administered in addition to the local standard of care for a duration of 26 weeks.

4 monitoring and follow-up

Throughout the 26-week period, the patient’s lung function will be monitored to evaluate the rate of decline in forced vital capacity (FVC).

Additional assessments will include monitoring for any adverse events, changes in quality of life, and other health outcomes.

5 completion of the study

At the end of the 26-week treatment period, the patient will undergo a final assessment to evaluate the overall impact of the treatment.

The study aims to determine the safety and effectiveness of Senicapoc compared to the placebo.

Who Can Join the Study?

  • You must have been diagnosed with Progressive Fibrotic Interstitial Lung Disease within the last 5 years.
  • You need to be able and willing to follow the study’s rules and have signed a form agreeing to participate.
  • You must be a male or female who is at least 40 years old.
  • You should have had a chest HRCT (a special type of lung scan) done within the last 24 months.
  • Your Forced Vital Capacity (FVC), which measures how much air you can exhale, should be more than 45% of what is expected for you. Also, your FEV1/FVC ratio should be more than 0.7 or above the lower limit of normal (LLN).
  • Your FVC should have decreased by at least 5% over the past year, based on at least three measurements taken within 6 to 24 months before joining the study.

Who Cannot Join the Study?

  • Patients who have a different lung condition that is not Progressive Fibrotic Interstitial Lung Disease cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who belong to a vulnerable population, which means they might need special protection or care, cannot participate.
  • Patients who are not able to follow the study procedures or take the study medication as required cannot participate.
  • Patients who have any other medical condition that might interfere with the study or make it unsafe for them cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Odense University Hospital Odense Denmark
Tartu University Hospital Tartu Estonia
Rigshospitalet Copenhagen Denmark
Azpnbj Utwzmuonpd Hofupzms Aarhus Denmark

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Denmark Denmark
Recruiting
01.08.2024
Estonia Estonia
Recruiting
01.08.2024

Trial locations

Investigated drugs:

Senicapoc is a medication being studied for its potential to help patients with Progressive Fibrotic Interstitial Lung Disease (ILD) or Idiopathic Pulmonary Fibrosis (IPF). The goal of using Senicapoc in this trial is to see if it can slow down the worsening of lung function, which is measured by how much air a person can exhale after taking a deep breath. This is done over a period of 26 weeks. Senicapoc is given in addition to the usual treatments that patients are already receiving for their condition.

Investigated diseases:

Progressive Fibrotic Interstitial Lung Disease – This disease is characterized by the gradual scarring and thickening of the lung tissue, which leads to a decline in lung function over time. The scarring, or fibrosis, makes it difficult for the lungs to work properly, reducing the ability to breathe deeply and efficiently. As the disease progresses, individuals may experience increasing shortness of breath and a persistent dry cough. The condition can affect the ability to perform daily activities due to reduced oxygen levels in the blood. It is considered a rare disease and can vary in severity and progression among individuals. The rate of lung function decline is often measured by the decrease in forced vital capacity (FVC), which is a key indicator of disease progression.

Trial ID:
2024-511131-97-00
Protocol code:
FIBROPOC
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy The Netherlands +1

  • A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +4